Importantly, mice dosed with a TLR9 antagonist displayed reduced symptoms of NASH, validating the importance of mtDNA release and TLR9 signalling in the pathogenesis of NASH 183. This evidence concerns the gene TLR9 and metabolic dysfunction-associated steatohepatitis.